Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

PURPOSE: The aim of this open-label, first-in-setting, randomized phase III trial was to evaluate the efficacy of alisertib, an investigational Aurora A kinase inhibitor, in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL). PATIENTS AND METHODS: Adult patients with relapsed/refrac...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Connor, Owen A., Özcan, Muhit, Jacobsen, Eric D., Roncero, Josep M., Trotman, Judith, Demeter, Judit, Masszi, Tamás, Pereira, Juliana, Ramchandren, Radhakrishnan, Beaven, Anne, Caballero, Dolores, Horwitz, Steven M., Lennard, Anne, Turgut, Mehmet, Hamerschlak, Nelson, d’Amore, Francesco A., Foss, Francine, Kim, Won-Seog, Leonard, John P., Zinzani, Pier Luigi, Chiattone, Carlos S., Hsi, Eric D., Trümper, Lorenz, Liu, Hua, Sheldon-Waniga, Emily, Ullmann, Claudio Dansky, Venkatakrishnan, Karthik, Leonard, E. Jane, Shustov, Andrei R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494247/
https://www.ncbi.nlm.nih.gov/pubmed/30707661
http://dx.doi.org/10.1200/JCO.18.00899

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494247/
https://www.ncbi.nlm.nih.gov/pubmed/30707661
http://dx.doi.org/10.1200/JCO.18.00899

Ejemplares similares